Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 62, 2002 - Issue 1
Submit an article Journal homepage
27
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Effects of octreotide on serum insulin-like growth factor I and insulin-like growth factor binding proteins in patients with cirrhosis

L. H. Ottesen Department of Hepatology V and Centre for Clinical Pharmacology and Medical Research Laboratory M (Diabetes and Endocrinology), Aarhus University Hospital; Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
,
J. Frystyk Department of Hepatology V and Centre for Clinical Pharmacology and Medical Research Laboratory M (Diabetes and Endocrinology), Aarhus University Hospital; Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
,
M. Kiszka-Kanowitz Department of Hepatology V and Centre for Clinical Pharmacology and Medical Research Laboratory M (Diabetes and Endocrinology), Aarhus University Hospital; Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
,
H. Grønbæk Department of Hepatology V and Centre for Clinical Pharmacology and Medical Research Laboratory M (Diabetes and Endocrinology), Aarhus University Hospital; Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
,
F. Bendtsen Department of Hepatology V and Centre for Clinical Pharmacology and Medical Research Laboratory M (Diabetes and Endocrinology), Aarhus University Hospital; Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
&
A. Flyvbjerg Department of Hepatology V and Centre for Clinical Pharmacology and Medical Research Laboratory M (Diabetes and Endocrinology), Aarhus University Hospital; Department of Medical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Denmark
Pages 39-47 | Published online: 08 Jul 2009

  • Shmueli E, Record CO, Albert KG. Liver disease, carbohydrate metabolism and diabetes. Baillieres Clin Endocrinol Metab 1992; 6: 719-43.
  • Bianchi G, Marchesini G, ZoIi M, Bugianesi E, abbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatol 1994; 20: 119-25.
  • Underwood LE, Clemmons DR, Maes M, D'Ercole AJ, Ketelslegers JM Regulation of somatomedinC/insulin-like growth factor I by nutrients. Horm Res 1986; 24: 166-176.
  • Goldstein S, Harp JB, Phillips LS. Nutrition and somatomedin. XXII: molecular regulation of insulinlike growth factor-I during fasting and refeeding in rats. J MoI Endocrinol 1991; 6: 33-43.
  • Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91: 391-6.
  • Baxter RC The insulin-like growth factors and their binding proteins. Comp Biochem Physiol [B] 1988; 91: 229-35.
  • Phillips LS, Pao CI, Villafuerte BC. Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucl Acid Res MoI Biol 1998; 60: 195-265.
  • Suwanickul A, Morris SL, Powell DR. Identification of an insulin-responsive element in the promoter of the human gene for insulin-like growth factor binding protein 1. J Biol Chem 1993; 268: 17063-8.
  • Wu A, Grant DB, Hambley J, Levi AJ. Reduced serum somatomedin activity in patients with chronic liver disease. Clin Sci Mol Med 1974; 47: 359-66.
  • Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol 1993; 88: 1744-8.
  • Gaufriez A, Reding P, Urbain D, Golstein J, Copinschi G. Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991; 14:317-321.
  • Mø11er S, Gronbaek M, Main K, Becker U, Skakkebeek NE. Urinary growth hormone (U-GH) excretion and serum insulin-like growth factor 1 (IGF-I ) in patients with alcoholic cirrhosis. J Hepatol 1993; 17: 315-20.
  • Donaghy A, Ross R, Gimson A, Hughes SG, Holly J, Williams R. Growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatol 1995; 21: 680-8.
  • Scharf JG, Schmilz F, Frystyk J, Skjserbk C, Moesus H, Blum WF, Ramadori G, Hartmann H. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 1996; 25: 689-99.
  • Bessern I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, Hochain P, Larricq J, Gourlaouen A, Ribard D, Kara NM, Legoux J-L, Pillegand B, Becker M-C, Di Constanze J, Metrau J-M, Silvain J-M, Silvain C, Beauchant M. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555-60.
  • Sung JJ, Chung SC, Yung MY, Lai CW, Lau JY, Lee YT, Leung VK, Li MK, Li AK. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopie ligation. Lancet 1995; 346: 1666-9.
  • D'Amico G, Politi F, Morabito A, D'Antoni A, Guerrera D, Giannuoli G, Traina M, Vizzini G, Pasta L, Pagliaro L. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatol 1998; 28: 1206-14.
  • Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 313: 1576-80.
  • Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, Chiodini PG, Liuzzi A. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J Clin Endocrinol Metab 1986; 63: 1348-53.
  • Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
  • Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Reg 1995; 5: 169-76.
  • Frystyk J, Skjærbæk C, Dinesen B, 0rskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Letters 1994; 348: 185-91.
  • Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulinlike growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Ann Biochemistry 1986; 154: 138-43.
  • Matthews DR, Hosker JP, Rudenski AS, Nayior BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
  • Matthews JN, Altaian DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230-5.
  • Schimpff RM, Lebrec D, Donnadieu M. Somatomedin production in normal adults and drrhotic patients. Acta Endocrinol (Copenh) 1977; 86: 355-62.
  • Mø11er S, Juul A, Becker U, Flyvbjerg A, Skakkebæk NE, Henriksen JH. Concentrations, release and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBPs), IGF-I and growth hormone in different vascular beds in patients with cirrhosis. J CBn Endocrinol Metab 1995; 80: 1148-57.
  • Malmlöf K, Cortova Z, Saxerholt H, ArrheniusNyberg V, Karlsson E, Larsson C, Klingström G, Skottner A. IGF-I and GH: metabolic effects during experimentally induced catabolism. In: The insulinlike growth factors and their regulatory proteins. Amsterdam: Elsevier Science; 1994. p. 401-8.
  • Grøfte T, Aagaard N, Greisen J, Schmilz O, Christiansen JS, 0rskov H, Vilstrup H. Insulin-like growth factor-I improves glucose metabolism and hepatic amino acid-cc conversion in patients with liver cirrhosis. Growth Horm IGF Res 2000; 10: 134 (Abstract).
  • Avgerinos A, Armonis A, Raptis S. Somatostatin and octreotide in the management of acute variceal hemorrhage. Hepatogastroenterol 1995; 42: 145-50.
  • Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, Flyvbjerg A, Bendtsen F. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. Hepatol 2001; 34: 471-7.
  • Ottesen LH, Bendtsen F, Flyvbjerg A. The insulinlike growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver 2001; 21: 350-6.
  • Barreca A, Cariola G, Ponzani P, Arvigo M, Foppiani L, Giordano G, Minute F. Effect of octreotide on circulating IGF-I Chromatographie profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clin Endocrinol 1995; 42: 161-7.
  • Yumi K, Fagin JA, Yamashita M, Fishbein MC, Shah PK, Kaul S, Niu W, Nilsson J, Cercek B. Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. Lab Invest 1997; 76: 329-38.
  • Lewitt MS, Denyer GS, Cponey GJ, Baxter RC. Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinol 1991; 129: 2254-6.
  • Ørskov H, Wolthers T, Grøfte T, Flyvbjerg A, Vilstrup H, Hamberg O. Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemia. J Clin Endocrinol Metab 1994; 78: 138-40.
  • Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor binding protein 1 (IGFBP-I) levels in acromegaly. J Clin Endocrinol Metab 1991; 73: 441-3.
  • Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factorbinding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992; 75: 1459-63.
  • Flyvbjerg A, Schuller AG, van Neck JW, Groffen C, 0rskov H, Drop SL. Stimulation of hepatic insulinlike growth factor-binding protein-1 and -3 gene expression by octreotide in rats. J Endocrinol 1995; 147:545-51.
  • Shen XY, Holt RI, Miell JP, Justice S, Portmann B, Postel-Vinay MC, Ross RJ. Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab 1998; 83: 2532-8.
  • Tygstrup N. Determination of the hepatic galactose elimination capacity after a single intravenous injection in man. The reproducibility and the influence of uneven distribution. Acta Physiol Scand 1963; 58: 162-72.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.